European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading

MT Newswires Live04-09 23:14

European equities traded in the US as American depositary receipts were tracking lower late Thursday morning, declining 0.48% to 1,803.06 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and pharmaceutical company Ascendis Pharma (ASND), which advanced 4% and 3.1% respectively. They were followed by oil and gas company Eni (E) and telecommunications company Nokia (NOK), which increased 3% and 0.3% respectively.

The decliners from continental Europe were led by biopharmaceutical company Grifols (GRFS) and software firm SAP (SAP), which dropped 4.4% and 3.8% respectively. They were followed by internet browser company Opera (OPRA) and biopharmaceutical company Cellectis (CLLS), which lost 3% and 2.5% respectively.

The gainers from the UK were led by biopharmaceutical company NuCana (NCNA) and oil and gas company BP (BP), which rose 5.5% and 2.2% respectively. They were followed by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Amarin (AMRN), which were up 1.8% and 0.5% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and pharmaceutical company Silence Therapeutics (SLN), which fell 12% and 4.3% respectively. They were followed by communications company WPP (WPP) and cruise line operator Carnival (CUK), which were down 3.7% and 3.3% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment